Seattle Genetics (NASDAQ: [[ticker:SGEN]]), the developer of targeted cancer drugs, said today it has submitted an application to the FDA for clearance to start selling its first product in the U.S. The company is attempting to bring brentuximab vedotin (SGN-35) on the market as a treatment for relapsed forms of Hodgkin’s disease, and relapsed forms of anaplastic large cell lymphoma. The company has asked for a faster-than-usual six-month regulatory review, which the FDA sometimes grants for groundbreaking or potentially lifesaving therapies.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
